Domů › Rakovina žaludku › Pennsylvania › Pittsburgh
Klinické studie Rakovina žaludku v Pittsburgh, PA
14 studií pro Rakovina žaludku hledá účastníky v lokalitách v Pittsburgh a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Distance-Based Exercise to Preserve Function and Prevent Disability
Probíhá nábor
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Probíhá náborFáze 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Probíhá náborFáze 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Probíhá náborFáze 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Probíhá náborFáze 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Probíhá náborFáze 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Probíhá náborFáze 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Probíhá náborFáze 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Probíhá náborFáze 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Probíhá náborFáze 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Probíhá náborFáze 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Probíhá náborFáze 1
- AHN West Penn Hospital, Pittsburgh
Studie Rakovina žaludku v jiných městech
- Houston, TX42 studií
- Boston, MA32 studií
- New York City, NY31 studií
- Nashville, TN28 studií
- Baldwin Park, CA22 studií
- Los Angeles, CA22 studií
- Arlington, VA20 studií
- Dallas, TX19 studií
- San Antonio, TX19 studií
- St. Louis, MO18 studií
- Grand Rapids, MI18 studií
- Washington, DC16 studií
Další studie v Pittsburgh
- Nemalobuněčný plicní karcinom48 studií
- Rakovina (všechny typy)41 studií
- Rakovina prsu39 studií
- Kolorektální karcinom32 studií
- Metastatický karcinom31 studií
- Melanom31 studií
- Rakovina vaječníků30 studií
- Rakovina endometria23 studií
- Rakovina prostaty23 studií
- Rakovina plic23 studií
- Squamózní buněčný karcinom hlavy a krku22 studií
- Mrtvice22 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.